s) 2009;27:LBA8002. 9. Herbst RS, Sun Y, Korfee S, et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small Journal of Thoracic Oncology • Volume 5, Number 12, Supplement 6, December 2010 Santa Monica Supplement Copyright © 2010 by the International Association for the Study of Lung Cancer S485 cell lung cancer (NSCLC): a randomized, double-blind phase III trial (ZODIAC). J Clin Oncol (Meeting Abstracts) 2009;27:CRA8003. 10. De Boer R, Arrieta O, Gottfried M, et al. Vandetanib plus pemetrexed versus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer (NSCLC): a randomized, double-blind phase III trial (ZEAL). J Clin Oncol (Meeting Abstracts) 2009;27: 8010. 11. Natale RB, Thongprasert S, Greco FA, et al. Vandetanib versus erlotinib in patients with advanced non-small cell lung cancer (NSCLC) after failure of at least one prior cytotoxic chemotherapy: a randomized, double-blind phase III trial (ZEST). J Clin Oncol (Meeting Abstracts) 2009;27:8009. 12. Bhargava P, Esteves B, Nosov DA, et al. Updated activity and safety results of a phase II randomized discontinuation trial (RDT) of AV-951, a potent and selective VEGFR1, 2, and 3 kinase inhibitor, in patients with renal cell carcinoma (RCC). J Clin Oncol (Meeting Abstracts) 2009;27:5032. 13. Gadgeel SM, Wozniak A, Edelman MJ, et al. Cediranib, a VEGF receptor 1, 2, and 3 inhibitor, and pemetrexed in patients (pts) with recurrent non-small cell lung cancer (NSCLC). J Clin Oncol (Meeting Abstracts) 2009;27:e19007. 14. Garland LL, Chansky K, Wozniak A, et al. SWOG S0509: a phase II study of novel oral antiangiogenic agent AZD2171 (NSC-732208) in malignant pleural mesothelioma. J Clin Oncol (Meeting Abstracts) 2009;27:7511. 15. Sandler A, Gray R, Perry M, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355: 2542–2550. Santa Monica Supplement Journal of Thoracic Oncology • Volume 5, Number 12, Supplement 6, December 2010 Copyright © 2010 by the International Association for the Study of Lung Cancer S486